Eduardo Yañez Ruiz

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 495 citations · Full text

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Laurence Albigès et al. · New England Journal of Medicine · 2023 · 142 citations · Full text

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios Α. Dimopoulos, P. Anttila, Marcelo Capra et al. · Blood · 2020 · 79 citations · Full text

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Michinori Ogura, Juan‐Manuel Sancho, Seok‐Goo Cho et al. · The Lancet Haematology · 2018 · 63 citations · Full text

Lymphoid Neoplasia, Oncology, Immune Checkpoint Inhibitor +8